Same news, different lens. We cut through the noise and hand you the overlooked ideas and the deeper read the crowd misses. Join 38,000+ investors seeing the markets differently.

We use cookies

Value The Markets uses cookies to run the site, understand how it is used and to fund our free content with advertising. You can choose which optional cookies to allow.

See our Privacy Policy for details of the cookies we use and how we use your data.

Customize

Essential cookies

There are some cookies that we have to include in order for certain web pages to function. For this reason, they do not require your consent.

vtm_cookie_consent

1 year

Used to store the user's cookie consent preferences.
value_the_markets_session

2 hours

Used to identify the user's browsing session.
XSRF-TOKEN

2 hours

Used to secure both the user and our website against cross-site request forgery attacks.

More details

Analytics cookies

We use these for internal research on how we can improve the service we provide for all our users. These cookies assess how you interact with our website.

_ga

1 year

Main cookie used by Google Analytics, enables a service to distinguish one visitor from another.
_ga_*

1 year

Used by Google Analytics to persist session state.
_gid

1 day

Used by Google Analytics to identify the user.

More details

Advertising cookies

Set by Google AdSense to serve and measure the adverts that keep our content free. Without them no adverts are shown.

__gads

1 year

Used by Google AdSense to deliver and measure adverts.
__gpi

1 year

Used by Google AdSense to personalise adverts.
IDE

1 year

Used by Google DoubleClick to measure advert performance.

More details

Articles

Tickers

Articles

Tickers

Articles

Tickers

Aptevo Therapeutics Inc

About Aptevo Therapeutics Inc

Latest Aptevo Therapeutics Inc Press Releases

Aptevo Reports Mipletamig Combination Therapy Enabled 21% of Frontline AML Patients to Advance to Potentially Curative Stem Cell Transplant

Aptevo to Showcase Multispecific Platform at SITC 2026 Annual Meeting

Aptevo Advances Next-Generation Trispecific Candidate Toward Clinical Development

Foremost Clean Energy and Aptevo Therapeutics Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

Financials & Earnings

A sharper way to see the markets in just 5 minutes.